Q2 FY2026 · ended Jun 30, 2026 · Revenue $752.75M, +37.7% YoY · Filed Aug 7, 2026
Natera, Inc. (NTRA) files with the SEC under industry code 8071, Services-Medical Laboratories. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $752.8 million and a net loss of $67.0 million. Free cash flow was -$8.6 million. As of Jun 30, 2026 it held $2.2 billion in cash and investments and $238.5 million in total debt.
Revenue
$752.75M
+37.7% vs year-ago quarter
Net income
$-66.97M
+33.7% vs year-ago quarter
Operating cash flow
$54.79M
+45.8% vs year-ago quarter
Free cash flow
$-8.64M
-174.0% vs year-ago quarter
EPS
$-0.47
+36.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
144.14M
+5.0% vs year-ago quarter
Net cash
$1.94B
Q2 FY2026
Operating margin
-10.7%
TTM
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- NTRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1604821
- Former names
- Natera, Inc. (until Nov 5, 2026)
Other Services-Medical Laboratories companies
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
- CareDx, Inc. CDNA
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $752.8M | $696.6M | $665.5M | $592.2M | $546.6M |
| Operating income | -$75.8M | -$93.5M | -$22.8M | -$97.6M | -$110.4M |
| Net income | -$67.0M | -$85.1M | $47.3M | -$87.5M | -$100.9M |
| Diluted EPS | -$0.47 | -$0.60 | $0.34 | -$0.64 | -$0.74 |
| Operating cash flow | $54.8M | $40.2M | $73.9M | $59.4M | $37.6M |
| Free cash flow | -$8.6M | $18.0M | $37.8M | $37.0M | $11.7M |
| Total assets | $2.7B | $2.6B | $2.4B | $1.8B | $1.8B |
| Total liabilities | $836.0M | $840.4M | $685.9M | $569.3M | $510.9M |
| Stockholders' equity | $1.8B | $1.8B | $1.7B | $1.3B | $1.2B |
| Cash and investments | $2.2B | $2.2B | $1.1B | $1.0B | $1.0B |
| Total debt | $238.5M | $240.1M | $214.4M | $198.7M | $196.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 6, 2026 | Jul 1, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Jun 16, 2026 | Jun 2, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 16, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 5, 2026 | Jun 2, 2026 |
All 1001 Natera, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.